Research output per year
Research output per year
- 14 results
Search results
-
2024
Pharma pours millions into the NHS for non-research work-but we don't know what the money is being spent on
Boytchev, H., Ozieranski, P. & Elsharkawy, M., 23 Oct 2024, In: BMJ (Clinical research ed.). 387, 3 p., q2264.Research output: Contribution to journal › Article › peer-review
-
2023
Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
Rickard, E., Carmel, E. & Ozieranski, P., 29 Mar 2023, In: BMJ Open. 13, 3, e061591.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (SciVal) -
Evaluation of Financial and Non-financial Conflicts of Interest and Quality of Evidence underlying Psoriatic Arthritis Clinical Practice Guidelines-Analysis of Personal Payments from Pharmaceutical Companies and Authors' Self-citation Rate in Japan and the United States
Mamada, H., Murayama, A., Kamamoto, S., Kaneda, Y., Yoshida, M., Sugiura, S., Yamashita, E., Kusumi, E., Saito, H., Sawano, T., Tanimoto, T., Vassar, M., Ozieranski, P. & Ozaki, A., 30 Jun 2023, In: Arthritis Care & Research. 75, 6, p. 1278-1286Research output: Contribution to journal › Article › peer-review
Open AccessFile15 Citations (SciVal)75 Downloads (Pure) -
Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database
Ozieranski, P., Saghy, E. & Mulinari, S., 1 Nov 2023, In: PLoS ONE. 18, 11 November, 27 p., e0290022.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (SciVal) -
2022
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
Mulinari, S., Pashley, D. & Ozieranski, P., 31 Dec 2022, In: Health Policy. 126, 12, p. 1256-1262Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (SciVal) -
A 'patient-industry complex'? Investigating the financial dependency of UK patient organisations on drug company funding
Ozieranski, P., Pitter, J. G., Rickard, E., Mulinari, S. & Csanadi, M., 1 Jan 2022, In: Sociology of Health and Illness. 44, 1, p. 188-210 23 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Citations (SciVal) -
Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
Mulinari, S. & Ozieranski, P., 30 Jun 2022, In: Big Data and Society. 9, 1, p. 1-14 14 p.Research output: Contribution to journal › Article › peer-review
Open Access13 Citations (SciVal) -
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
Pashley, D., Ozieranski, P. & Mulinari, S., 1 Jul 2022, In: International Journal of Health Services. 52, 3, p. 347-362 16 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Citations (SciVal) -
How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
Ozaki, A., Murayama, A., Harada, K., Saito, H., Sawano, T., Tanimoto, T. & Ozieranski, P., 3 Jan 2022, In: Frontiers in Public Health. 9, 762637.Research output: Contribution to journal › Article › peer-review
Open Access6 Citations (SciVal) -
Tip of the Iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
Ozieranski, P., Martinon, L., Jachiet, P.-A. & Mulinari, S., 31 Dec 2022, In: International Journal of Health Policy and Management. 11, 12, p. 2842-2859 18 p.Research output: Contribution to journal › Article › peer-review
Open Access9 Citations (SciVal) -
2021
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: A European policy review
Ozieranski, P., Martinon, L., Jachiet, P.-A. & Mulinari, S., 16 Dec 2021, In: BMJ Open. 11, 12, e053138.Research output: Contribution to journal › Article › peer-review
Open Access18 Citations (SciVal) -
A hidden web of policy influence: The pharmaceutical industry’s engagement with UK’s All-Party Parliamentary Groups
Rickard, E. & Ozieranski, P., 24 Jun 2021, In: PLoS ONE. 16, 6 , e0252551.Research output: Contribution to journal › Article › peer-review
Open Access12 Citations (SciVal) -
Drug company payments to General Practices in England: Cross-sectional and social network analysis
Saghy, E., Mulinari, S. & Ozieranski, P., 7 Dec 2021, In: PLoS ONE. 16, 12, p. e0261077Research output: Contribution to journal › Article › peer-review
Open Access4 Citations (SciVal) -
Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries
Mulinari, S., Martinon, L., Jachiet, P.-A. & Ozieranski, P., Jul 2021, In: Health Policy. 125, 7, p. 915-922 8 p.Research output: Contribution to journal › Article › peer-review
Open Access27 Citations (SciVal)